Benjamin Ping, the new general manager of Takeda Vietnam, talked to VIR’s Tung Anh about his leadership approach to foster ...

Chinese biotech start-ups are going up against Western drug makers - and they could win A decade ago, treating cancer with personalised mRNA vaccines seemed like a US$1 million gamble per patient, a ...

The American Hospital Association (AHA) and the Association for Advancement of Medical Instrumentation (AAMI) brought together a small group composed of hospital and health system leaders, device ...

Dr. Nisha Acharya got a letter from the National Institutes of Health terminating her grant to study the safety and ...

"An adversarial collaboration on vaccines could serve as a model," write Drs. Christopher M. Worsham and Anupam B. Jena.

Full-year results and business updateClinical proof of principle obtained in Phase I adjuvant head and neck cancer trial with individualized ...

The EU is introducing new regulations (EDIRPA and EDIP) to structure military procurement through pooled orders coordinated by the ...

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

RNA cancer vaccines are at the forefront of next-generation cancer immunotherapy, showcasing significant potential.

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation ...

Researchers have identified antibodies that could lead to a broadly protective norovirus vaccine and new treatment options.

SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the full year 2024.